BioLineRx (BLRX) Income from Continuing Operations (2011 - 2026)
BioLineRx (BLRX) posted quarterly Income from Continuing Operations of 2236000.0 for Q4 2025, up 29.84% year-over-year from 1722119.86 in Q4 2024, and down 128.86% quarter-over-quarter from 977000.0 in Q3 2025.
Powered by 
Analysis
BioLineRx (BLRX) Income from Continuing Operations (2011 - 2026) Analysis & Trends
BioLineRx's Income from Continuing Operations history runs 14 years deep, the most recent figure standing at 2236000.0 for Q4 2025.
- In Q4 2025, Income from Continuing Operations rose 29.84% year-over-year to 2236000.0; the TTM figure through Dec 2025 stood at 2026000.0 (up 78.03% YoY), while the FY2025 annual figure was 2026000.0, up 78.03% from the prior year.
- Income from Continuing Operations for Q4 2025 stood at 2236000.0, down from 977000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 5127000.0 in Q1 2025, with the low at 23057000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 6019000.0 (2021), against an average of 5527950.0.
- Peak annual rise in Income from Continuing Operations reached 836.64% in 2025, while the deepest fall reached 533.92% in 2025.
- BioLineRx's Income from Continuing Operations stood at 6134000.0 in 2021, then declined by 8.15% to 6634000.0 in 2022, then sank by 247.56% to 23057000.0 in 2023, then jumped by 86.18% to 3187000.0 in 2024, then advanced by 29.84% to 2236000.0 in 2025.
- Business Quant data shows BLRX's Income from Continuing Operations at 2236000.0 in Q4 2025, 977000.0 in Q3 2025, and 3940000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | BioLineRx | 6.68 Bn | 6.68 Bn | 235,000.00 | -3.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.23 Mn |
| Mar 31, 2026 | -2.55 Mn |
| Dec 31, 2025 | -2.80 Mn |
| Sep 30, 2025 | -1.53 Mn |
| Jun 30, 2025 | -1.54 Mn |
| Mar 31, 2025 | -1.68 Mn |
| Dec 31, 2024 | 391,000.00 |
| Sep 30, 2024 | -3.33 Mn |
| Jun 30, 2024 | -3.15 Mn |
| Mar 31, 2024 | -3.33 Mn |
| Dec 31, 2023 | -18.72 Mn |
| Sep 30, 2023 | -11.21 Mn |
| Jun 30, 2023 | -8.14 Mn |
| Mar 31, 2023 | -7.39 Mn |
| Dec 31, 2022 | -6.63 Mn |
| Sep 30, 2022 | -6.70 Mn |
| Jun 30, 2022 | -7.14 Mn |
| Mar 31, 2022 | -5.83 Mn |
| Dec 31, 2021 | -6.13 Mn |
| Sep 30, 2021 | -5.90 Mn |